- Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden.
- Durable clinical responses were associated with improvements in patient-reported measures of fatigue.
- Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reductions in spleen volume and improved total symptom scores.
Keros Therapeutics Presented Additional Data From Its Two Ongoing Phase 2 Trials Of Elritercept (KER-050), For Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes And Myelofibrosis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.